FAFGX | NGDLX | FAFGX / NGDLX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 4 years | 15 years | - |
Gain YTD | 21.910 | 18.553 | 118% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 1000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 290B | 2.54B | 11,435% |
Annual Yield % from dividends | 0.69 | 0.38 | 181% |
Returns for 1 year | 30.50 | 28.07 | 109% |
Returns for 3 years | 1.64 | 4.34 | 38% |
Returns for 5 years | N/A | 61.10 | - |
Returns for 10 years | N/A | 49.65 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
NSBFX | 65.97 | 0.01 | +0.02% |
Nuveen Dividend Growth R6 | |||
CLPCX | 11.57 | -0.05 | -0.43% |
Catalyst Nasdaq-100 Hedged Equity C | |||
ETNHX | 36.76 | -0.17 | -0.46% |
Eventide Healthcare & Life Sciences N | |||
MYINX | 8.02 | -0.05 | -0.62% |
NYLI WMC International Rsrch Eq Inv Cl | |||
TVRRX | 80.98 | -0.57 | -0.70% |
Thornburg Small/Mid Cap Core R5 |